SCHEMBL2862981

SCHEMBL2862981

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccc(Oc5ccccc5)cc4C)nc3c3ccc(OC(C)C)cc32)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.39
PLA2G2A P14555 2/20 0.38
S1PR3 Q99500 2/20 0.37
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE1A P54750 3/20 0.36
PDE1B Q01064 3/20 0.36
PDE1C Q14123 3/20 0.36
TP53 P04637 2/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.35
P2RX7 Q99572 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858941 0.90 GAA (0.38) PLA2G10PLA2G2AS1PR3BLMSMN1; SMN2
SCHEMBL2867619 0.90 BCL2 (0.40) PLA2G10PLA2G2AS1PR3BLMSMN1; SMN2
SCHEMBL2866812 0.90 P2RX4 (0.44) BLMSMN1; SMN2TP53POLBALDH1A1
SCHEMBL2857641 0.87 PDE1B (0.38) PLA2G10PLA2G2APDE1APDE1BPDE1C
SCHEMBL2861122 0.86 PDE1A (0.39) PLA2G10PLA2G2APDE1APDE1BPDE1C
SCHEMBL2865416 0.85 S1PR3 (0.41) PLA2G10PLA2G2AS1PR3PDE1APDE1B
SCHEMBL2862709 0.84 RXFP1 (0.42) PLA2G10S1PR3PDE1APDE1BPDE1C
SCHEMBL2856173 0.84 MEN1 (0.41) PLA2G10PLA2G2AS1PR3SMN1; SMN2TP53
SCHEMBL2862341 0.84 PDE1B (0.40) PLA2G10S1PR3PDE1APDE1BPDE1C
SCHEMBL2864310 0.84 ALDH1A1 (0.37) BLMSMN1; SMN2ALDH1A1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 PLA2G10 4186/4885PLA2G2A 3916/4885S1PR3 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.